Long-term Clinical Relevance of de Novo Donor-Specific Antibodies after Pediatric Liver Transplantation

Transplantation

Volumn 99, Issue 9, 2015, Pages 1876-1881

  Grabhorn, Enke ^a   Binder, Thomas M C ^a   Obrecht, Denise ^a   Brinkert, Florian ^a   Lehnhardt, Anja ^a   Herden, Uta ^a   Peine, Sven ^a   Nashan, Bjorn ^a   Ganschow, Rainer ^b   Briem Richter, Andrea ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; HLA ANTIGEN CLASS 2; UNCLASSIFIED DRUG; ALLOANTIBODY; BIOLOGICAL MARKER;

ADOLESCENT; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; CHILD; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RETRANSPLANTATION; RETROSPECTIVE STUDY; SCHOOL CHILD; ADULT; ADVERSE EFFECTS; AGE; BIOPSY; BLOOD; CHRONIC DISEASE; FLUORESCENT ANTIBODY TECHNIQUE; GERMANY; IMMUNOLOGY; INFANT; PREDICTIVE VALUE; RISK FACTOR; SEROLOGY; TERTIARY CARE CENTER; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; BIOLOGICAL MARKERS; BIOPSY; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GERMANY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INFANT; ISOANTIBODIES; LIVER TRANSPLANTATION; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SEROLOGIC TESTS; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944323079     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000638     Document Type: Article

References (34)

1. Grabhorn E, Schulz A, Helmke K, et al. Short-and long-term results of liver transplantation in infants aged less than 6 months. Transplantation 2004;78:235.
2. Venick RS, Farmer DG, McDiarmid SV, et al. Predictors of survival following liver transplantation in infants: a single-center analysis of more than 200 cases. Transplantation 2010;89:600.
3. Bishara A, Brautbar C, Eid A, Scherman L, Ilan Y, Safadi R. Is presensitization relevant to liver transplantation outcome? Hum Immunol 2002;63:742.
4. Muro M, López-Alvarez MR, Campillo JA, et al. Influence of human leukocyte antigen mismatching on rejection development and allograft survival in liver transplantation: is the relevance of HLA-A locus matching being underestimated? Transpl Immunol 2012;26:88.
5. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012;12:1504.
6. Gloor J, Cosio F, Lager DJ, Stegall MD. The spectrum of antibodymediated rejection renal allograft injury. Implications for treatment. Am J Transplant 2008;8:1367.
7. Kittleson MM, Kobashigawa JA. Antibody-mediated rejection. Curr Opin Organ Transplant 2012;17:551.
8. Lobo P, Spencer C, Douglas MT, Stevenson WC, Pruett TL. The lack of long-term detrimental effects on liver allografts caused by donor-specific anti-HLA antibodies. Transplantation 1993;55:1063.
9. Donaldson PT, Thomson LJ, Heads A, et al. IgG donor-specific crossmatches are not associated with graft rejection or poor graft survival after liver transplantation. An assessment by cytotoxicity and flow cytometry. Transplantation 1995;60:1016.
10. Muro M, Marin L, Miras M, et al. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre. Transpl Immunol 2005;14:91.
11. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008;14:554.
12. Lan X, Zhang MM, Pu CL, et al. Impact of human leukocyte antigen mismatching on outcomes of liver transplantation: a meta-analysis. World J Gastroenterol 2010;16:3457.
13. ÒLeary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011;11:1868.
14. Opelz G, Dohler B, Susal C. Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study. Hum Immunol 2009;70:627.
15. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012;18:1333.
16. Saito T, Mizuta K, Hishikawa S, et al. Lymphocytotoxic crossmatch in pediatric living donor liver transplantation. Pediatr Transplant 2009;13:194.
17. Goh A, Scalamogna M, De Feo T, Poli F, Terasaki PI. Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl 2010;16:308.
18. Banff Working GroupDemetris AJ, Adeyi O, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006;44:489.
19. Iwatsuki S, Iwaki Y, Kano T, et al. Successful liver transplantation from crossmatch-positive donors. Transplant Proc 1981;13:286.
20. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011;11:500.
21. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013;13:1541.
22. O'Leary JG, Kaneku H, Jennings LW, et al. Preformed class II donorspecificantibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013;19:973.
23. Iacob S, Cicinnati VR, Dechene A, et al. Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. Liver Int 2012;32:1253.
24. Neumann UP, Lang M, Moldenhauer A, et al. Significance of a T-lymphocytotxic crossmatch in liver and combined liver-kidney transplantation. Transplantation 2001;71:1163.
25. Kasahara M, Kiuchi T, Uryuhara K, et al. Role of HLA compatibility in pediatric living-related liver transplantation. Transplantation 2002; 74:1175.
26. Yamada H, Kondou H, Kimura T, et al. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation. Pediatr Transplant 2012;16:858.
27. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012;12:171.
28. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. J Am Med Assoc 2012; 307:283.
29. Girnita A, Mazariegos GV, Castellaneta A, et al. Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Human Immunol 2010;71:274.
30. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013;369:1215.
31. Roelen DL, Doxiadis IIL, Claas FHJ. Detection and clinical relevance of donor-specific HLA antibodies: a matter of debate: review. Transpl Int 2012;25:604.
32. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor specific antibodies. Liver Transpl 2011;17:357.
33. Morales-Buenrostro LE, Terasaki PI,Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008;86:1111.
34. Singh N, Djamali A, Lorentzen D, et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010;90:1079.